Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07048574 · ClinicalTrials.gov registry record

TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

A clinical trial of Cystic Fibrosis (CF), sponsored by State University of New York at Buffalo.

Recruiting
Registry status
600
Enrollment target
13
Study locations

NCT07048574: Recruiting study of Cystic Fibrosis (CF), sponsored by State University of New York at Buffalo.

NCT07048574 is a study of Cystic Fibrosis (CF) that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 600 participants, above the 98-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (512% higher). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07048574, a study of Cystic Fibrosis (CF), is actively recruiting participants, sponsored by State University of New York at Buffalo.

RECRUITING
Registry status
600 participants
Enrollment target
13
Study locations

Study Summary

This is a longitudinal, observational epidemiological study designed to estimate the prevalence of depression, anxiety, and behavior problems in children ages 18 months through 11 years with cystic fibrosis (CF).

Primary Outcome

Estimate the national prevalence of depression, anxiety, and behavioral problems among children with cystic fibrosis aged 18 months through 11 years using the Behavior Assessment System for Children, Third Edition (BASC-3). At the baseline assessment (Time 1), parents complete the age-appropriate BASC-3 Parent Rating Scale, and children aged 8-11 years complete the BASC-3 Self-Report of Personality. BASC-3 classifications of emotional and behavioral symptoms will be used to estimate the prevalen

Conditions Studied

Study Locations (13)

Florida

  • Joe DiMaggio - Hollywood
  • Nemours Foundation - Orlando

California

  • Children's Hospital of Orange County - Orange

Colorado

  • Children's Hospital Colorado - Aurora

Indiana

  • Indiana University - Bloomington

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • University at Buffalo - Buffalo

North Carolina

  • University of North Carolina School of Medicine - Chapel Hill

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-06-02
Est. Completion 2028-06-30

What NCT07048574 shows while recruiting

NCT07048574 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 98-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (512% higher).

The record links to 1 condition, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 0 interventions.

NCT07048574 lists 13 locations in 12 states (Florida, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT07048574 about?

NCT07048574 is a clinical study titled "TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age". This is a longitudinal, observational epidemiological study designed to estimate the prevalence of depression, anxiety, and behavior problems in children ages 18 months through 11 years with cystic fibrosis (CF).

What is the current status of trial NCT07048574?

This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-06-02. Estimated completion is 2028-06-30.

What conditions does trial NCT07048574 study?

This clinical trial studies the following conditions: Cystic Fibrosis (CF).

Who is sponsoring clinical trial NCT07048574?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07048574 being conducted?

This trial has 13 study locations across California, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis (CF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07048574's enrollment target sits among peer trials

600 1st of 14 higher than 14 of 14 other Cystic Fibrosis (CF) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis (CF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07048574, the US trial registry maintained by the National Library of Medicine. NCT07048574 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.